Komori
Revision of earnings forecasts4552JCR Pharmaceuticals Co.,Ltd.Pharmaceuticals

Notice Regarding Revisions to Full-Year Consolidated Earnings Forecast

The full-year consolidated earnings forecast for the fiscal year ending March 2026 has been revised upward to net sales of ¥40.3 billion, up ¥800 million from the previous forecast, operating profit of ¥500 million, ordinary profit of ¥1.1 billion, and net income attributable to owners of the parent of ¥2.1 billion. Firm product sales and expected foreign exchange gains are expected to boost profit.

Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
800
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2026 · Full yearPrevious forecast published 28 January 2026
Net Sales39,500→40,300million
+2.0%
Operating profit400→500million
+25.0%
Ordinary income400→1,100million
+175.0%
Profit attributable to owners of the parent1,600→2,100million
+31.3%
Net income per share13.12→17.87yen and sen
+36.2%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

Product sales are expected to remain firm. Gross profit and selling, general and administrative expenses are expected to be broadly in line with assumptions, while foreign exchange gains are expected to be recorded as non-operating income.

Previous-period resultsNet sales: ¥33,072 million; operating loss: ¥6,650 million; ordinary loss: ¥7,477 million; net loss attributable to owners of the parent: ¥4,759 million; net loss per share: ¥38.43
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥39,500 million → ¥40,300 million(+2.0%)
Operating profit¥400 million → ¥500 million(+25.0%)
Ordinary income¥400 million → ¥1,100 million(+175.0%)
Profit attributable to owners of the parent¥1,600 million → ¥2,100 million(+31.3%)
Net income per share13.12 yen and sen → 17.87 yen and sen
Fiscal Period CoveredFiscal year ending March 2026
Period CoveredFull year
Publication date of previous forecast28 January 2026
Previous-period resultsNet sales: ¥33,072 million; operating loss: ¥6,650 million; ordinary loss: ¥7,477 million; net loss attributable to owners of the parent: ¥4,759 million; net loss per share: ¥38.43
Reason for the revisionProduct sales are expected to remain firm. Gross profit and selling, general and administrative expenses are expected to be broadly in line with assumptions, while foreign exchange gains are expected to be recorded as non-operating income.
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The sales forecast was revised upward as product sales are expected to remain firm. Gross profit and selling, general and administrative expenses are expected to be broadly in line with assumptions, while foreign exchange gains are expected to be recorded as non-operating income, prompting upward revisions to operating profit, ordinary profit and net income.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to Full-Year Consolidated Earnings Forecast | JCR Pharmaceuticals Co.,Ltd. (4552) timely disclosure | Komori